Finasteride-d9

Finasteride-d9 is intended for use as an internal standard for the quantification of finasteride (Cay-14938) by GC- or LC-MS. Finasteride is a 4-azasteroid competitive inhibitor of 5alpha-reductase type II (IC50 = 4.2 nM) and a derivative of testosterone. It is 100-fold selective for 5alpha-reductase type II over type I. Finasteride (10 µM) does not affect the growth of androgen-refractory PC3 prostate cancer cells but increases the protein levels of Nrf2 and heme oxygenase-1 (HO-1). It decreases prostatic diameter and volume, as well as dihydrotestosterone, but not testosterone, serum levels in dogs with spontaneous benign prostatic hypertrophy when administered at doses of 0.1 and 0.5 mg/kg. Finasteride reduces testosterone-induced type I procollagen and TGF-beta1 protein levels in cultured human scalp dermal fibroblasts in a model of androgenic alopecia when applied at a concentration of 0.1 µM. Formulations containing finasteride have been used in the treatment of benign prostatic hyperplasia and androgenic alopecia in men.Formal Name: (4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-dimethyl-N-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide. CAS Number: 1131342-85-2. Molecular Formula: C23H27D9N2O2. Formula Weight: 381.6. Purity: >99% deuterated forms (d1-d9). Formulation: (Request formulation change), A solid. Solubility: Chloroform: slightly soluble, Methanol: slightly soluble. SMILES: O=C(NC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])[C@H]1CC[C@]2([H])[C@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@]4([H])[C@]3(C)C=CC(N4)=O. InChi Code: InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1/i1D3,2D3,3D3. InChi Key: DBEPLOCGEIEOCV-BSRKVXQGSA-N.